(±)-tert-butyl trans-3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylate | 849674-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (±)-tert-butyl trans-3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylate
• 英文别名: trans-tert-butyl 3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylate；(trans)-3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester；tert-butyl-3-hydroxy-4-(4-fluorophenyl)pyrrolidine-1-carboxylate；Trans-tert-butyl 3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylate；tert-butyl (3R,4S)-3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylate
• CAS: 849674-13-1
• 化学式: C₁₅H₂₀FNO₃
• 分子量: 281.327
• InChiKey: CPIDDCULCPYQGQ-QWHCGFSZSA-N

物化性质

• 沸点：
  386.1±42.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (±)-tert-butyl trans-3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylate 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 甲苯 为溶剂， 反应 16.5h， 生成 tert-butyl (3R,4R)-3-{[3,5-bis(trifluoromethyl)benzoyl]oxy}-4-(4-fluorophenyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DU RECEPTEUR DE LA TACHYKININE A BASE DE PHENYLE PYRROLIDINE ETHER

  摘要：

  公开号：

  WO2005032464A3
• 作为产物：
  描述：

  N-Boc-3-吡咯啉 在 copper(l) iodide 、 碘 、 magnesium 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 12.75h， 生成 (±)-tert-butyl trans-3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylate
  参考文献：
  名称：

  使用手性烷氧基胺作为预催化剂对仲醇进行高对映选择性有机催化氧化动力学拆分：催化剂结构、活性物质和底物范围

  摘要：

  描述了使用手性烷氧基胺作为预催化剂的外消旋仲醇的对映选择性有机催化氧化动力学拆分 (OKR) 的开发和表征。已经合成了许多手性烷氧基胺，它们在 OKR 中的结构-对映选择性相关性研究使我们确定了一种有前途的前催化剂，即 7-苄基-3-正丁基-4-氧杂-5-氮杂高金刚烷，它提供了各种手性脂肪族仲醇（ee 高达 >99%，k(rel) 高达 296）。在一项机理研究中，含氯氧铵物种被确定为烷氧基胺预催化剂原位生成的活性物种，并且发现氯原子对于高反应性和对映选择性至关重要。

  DOI：

  10.1021/ja509766f

文献信息

• De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors
  作者：Ying Wang、Hongyu Zhao、Jason T. Brewer、Huanqiu Li、Yanbin Lao、Willi Amberg、Berthold Behl、Irini Akritopoulou-Zanze、Justin Dietrich、Udo E. W. Lange、Frauke Pohlki、Carolin Hoft、Wilfried Hornberger、Stevan W. Djuric、Jens Sydor、Mario Mezler、Ana Lucia Relo、Anil Vasudevan

  DOI：10.1021/acs.jmedchem.8b00295

  日期：2018.9.13

  may offer putative treatments for schizophrenia and other disorders associated with hypofunction of the glutaminergic N-methyl-d-aspartate (NMDA) receptor. Herein, we describe the synthesis and biological evaluation of a series of 3,4-disubstituted pyrrolidine sulfonamides as competitive GlyT1 inhibitors that arose from de novo scaffold design. Relationship of chemical structure to drug–drug interaction

  甘氨酸转运蛋白1（GlyT1）抑制剂的开发可能为精神分裂症和与谷氨酰胺N-甲基-d功能低下相关的其他疾病提供推定的治疗方法-天冬氨酸（NMDA）受体。在本文中，我们描述了一系列3,4-二取代的吡咯烷磺酰胺类化合物的合成和生物学评估，它们是从头开始设计时产生的竞争性GlyT1抑制剂。机械地研究了化学结构与药物相互作用（DDI）和生物活化的关系。将鼠类研究策略性地纳入筛选漏斗中，以通过离体结合研究提供对体内靶标占有率（TO）的早期评估。源自迭代结构-活性关系（SAR）研究的先进化合物在离体结合研究中具有很高的效力，并且具有良好的大脑渗透能力，有望在体内具有初步的疗效，可接受的临床前药代动力学以及可控的DDI和生物活化作用。
• [EN] PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY<br/>[FR] DÉRIVÉS DE PYRROLIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION EN THÉRAPIE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014140310A1

  公开（公告）日：2014-09-18

  The present invention relates to pyrrolidine derivatives of formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

  本发明涉及式(I)的吡咯烷衍生物，或其生理耐受盐。该发明涉及包含此类吡咯烷衍生物的药物组合物，以及利用此类吡咯烷衍生物进行治疗的用途。这些吡咯烷衍生物是GlyT1抑制剂。
• Phenyl pyrrolidine ether tachykinin receptor antagonists
  申请人：DeVita J. Robert

  公开号：US20070043015A1

  公开（公告）日：2007-02-22

  The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, depression, and anxiety.

  本发明涉及某些苯基吡咯烷醚化合物，其作为神经激肽-1（NK-1）受体拮抗剂和快速激肽，特别是物质P的抑制剂具有用途。本发明还涉及包含这些化合物作为活性成分的制药配方以及这些化合物及其配方在治疗某些疾病，包括呕吐、抑郁和焦虑方面的应用。
• The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine
  作者：Peter Lin、Lehua Chang、Robert J. DeVita、Jonathan R. Young、Ronsar Eid、Xinchun Tong、Song Zheng、Richard G. Ball、Nancy N. Tsou、Gary G. Chicchi、Marc M. Kurtz、Kwei-Lan C. Tsao、Alan Wheeldon、Emma J. Carlson、WaiSi Eng、H. Donald Burns、Richard J. Hargreaves、Sander G. Mills

  DOI：10.1016/j.bmcl.2007.06.085

  日期：2007.9

  SAR studies on amides, ureas, and vinylogous amides derived from pyrrolidine led to the discovery of several potent hNK(1) antagonists. One particular vinylogous amide (45b) had excellent potency, selectivity, pharmacokinetic profile, and functional activity in vivo. An in vivo rhesus macaque brain receptor occupancy PET study for compound 45b revealed an estimated Occ(90) similar to 300 ng/ml. (c) 2007 Elsevier Ltd. All rights reserved.
• Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1)
  作者：Sean T. Murphy、Gordon Alton、Simon Bailey、Sangita M. Baxi、Benjamin J. Burke、Thomas A. Chappie、Jacques Ermolieff、RoseAnn Ferre、Samantha Greasley、Michael Hickey、John Humphrey、Natasha Kablaoui、John Kath、Steven Kazmirski、Michelle Kraus、Stan Kupchinsky、John Li、Laura Lingardo、Matthew A. Marx、Dan Richter、Steven P. Tanis、Khanh Tran、William Vernier、Zhi Xie、Min-Jean Yin、Xiao-Hong Yu

  DOI：10.1021/jm201019k

  日期：2011.12.22

  Analogues substituted with various amines at the 6-position of the pyrazine ring on (4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrazin-2-ylmethanone were discovered as potent and selective inhibitors of PDK1 with potential as anticancer agents. An early lead with 2-pyridine-3-ylethylamine as the pyrazine substituent showed moderate potency and selectivity. Structure-based drug design led to improved potency and selectivity against PI3K alpha through a combination of cyclizing the ethylene spacer into a saturated, five-membered ring and substituting on the 4-position of the aryl ring with a fluorine. ADME properties were improved by lowering the lipophilicity with heteroatom replacements in the saturated, five-membered ring. The optimized analogues have a PDK1 K-i of 1 nM and >100-fold selectivity against PI3K/AKT-pathway kinases. The cellular potency of these analogues was assessed by the inhibition of AKT phosphorylation (T308) and by their antiproliferation activity against a number of tumor cell lines.